bet for dollars->a dream?, page-5

===FDA Approval Timeline===

****Achieved to date...****

1. CVac™ commenced research in 1996.

2. Phase I trials commenced in 2001. Trails conducted on 14 patients with a variety of malignant tumours

3. Phase II trials completed in 2007. Trials conducted on 21 patients with elevated CA125 levels (a key biomarker for disease activity)

4. FDA pre-Investigational New Drug Application (preIND) meeting request complete August 2008. A PreIND meeting is a key milestone in FDA approval process

5. FDA pre-Investigational New Drug Application (preIND) meeting, successfully completed - October 2008

***Upcoming...***

1. Commence US FDA IND application for CVac™ - May 2009

2. US FDA grant of Investigational New Drug Application (IND) for CVac™ ovarian cancer treatment - mid-2009. Confirms data, manufacturing and statistics all to FDA standards

3. Pivotal Clinical Trial to commence – mid-2009. Trial to be conducted on total of 340 patients(approx) in 3 tranches

4. FDA grant of Biological Licence Authority (BLA). BLA allows company to commence charging for use of Cvac™

5. Full commercialisation of Cvac™. Licensing or sale to pharmaceutical/drug major